(Q36419566)

14 August 2017

1 reference

title

Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management (English)

1 reference

14 August 2017

0 references

Dean M Wingerchuk

1

1 reference

14 August 2017

publication date

1 March 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

333-346

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

14 August 2017

1 reference

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Depressive symptoms in a treated multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Depression in multiple sclerosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

21 January 2018

Management of hair loss

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Identifying and treating patients with suboptimal responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Mitoxantrone treatment of multiple sclerosis: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.3.333

21 January 2018

Identifiers

DOI

10.1586/14737175.6.3.333

1 reference

14 August 2017

1 reference